Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$5.36M, compared with -$309.57K a year earlier.
Context
- Net debt amounted to 92.5% of total assets at the end of Q1 FY2026, up 29.5 pp from a year earlier.
- Net debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -1630.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (6.81M) USD
- Year-over-year change
- -481.0%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.81M) | -481.0% |
| FY2024 | 2024-12-31 | (1.17M) | -1275.4% |
| FY2023 | 2023-12-31 | 99.77K | -82.8% |
| FY2022 | 2022-12-31 | 580.37K | +386.1% |
| FY2021 | 2021-12-31 | 119.4K | — |
Net Debt vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 net debt of -$5.36M is the 4th highest of the 6 companies compared; the peer median is -$5.11M.
- Its year-over-year change of -1630.7% is the lowest of 6, against a peer median of -129.4%.
- Net debt amounts to 92.5% of total assets for TELO, versus a peer median of 76.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $140.02M | -5.3% | +58.0% | 106.5% | |
| Mar 2026 | -$3.02M | -473.2% | — | 0.9% | |
| Mar 2026 | -$5.11M | -129.4% | — | 25.8% | |
| Mar 2026 | -$5.36M | -1630.7% | — | 92.5% | |
| Mar 2026 | -$19.85M | -4.5% | — | 76.9% | |
| Mar 2026 | -$60.63M | -326.8% | — | 96.1% | |
| Peer median (excluding TELO) | -$5.11M | -129.4% | +58.0% | 76.9% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.